PT  - JOURNAL ARTICLE
AU  - Alves, Katia
AU  - Plested, Joyce S
AU  - Galbiati, Shirley
AU  - Chau, Gordon
AU  - Cloney-Clark, Shane
AU  - Zhu, Mingzhu
AU  - Kalkeri, Raj
AU  - Patel, Nita
AU  - Smith, Kathy
AU  - Marcheschi, Alex
AU  - Pfeiffer, Susan
AU  - McFall, Heather
AU  - Smith, Gale
AU  - Glenn, Gregory M.
AU  - Dubovsky, Filip
AU  - Mallory, Raburn M.
AU - the Novavax 2019nCoV-101 Study Group
TI  - Immunogenicity and safety of a 4<sup>th</sup> homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial
AID  - 10.1101/2022.11.18.22282414
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.18.22282414
4099  - http://medrxiv.org/content/early/2022/11/20/2022.11.18.22282414.short
4100  - http://medrxiv.org/content/early/2022/11/20/2022.11.18.22282414.full
AB  - Background The emergence of SARS-CoV-2 variants has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX-CoV2373 (5µg SARS-CoV-2 rS + 50µg Matrix-M™ adjuvant) was evaluated to determine induction of cross-reactive antibodies to variants of concern.Methods A phase 2 randomized study assessed a fourth dose of NVX-CoV2373 in adults 18–84 years of age (2-dose primary series followed by third and fourth doses at 6-month intervals). Local/systemic reactogenicity was assessed the day of vaccination and for 6 days thereafter. Unsolicited adverse events (AEs) were reported. Immunogenicity was measured before, and 14 days after, fourth dose administration using anti-spike neutralization assays against the ancestral SARS-CoV-2 strain and Omicron sublineages. Antigenic cartography assessed antigenic distances between ancestral and variant strains.Results Among 1283 enrolled participants, 258 were randomized to receive the 2-dose primary series, of whom 104 received a third dose, and 45 received a fourth dose of NVX-CoV2373. The incidence of local/systemic reactogenicity events increased after the first three doses of NVX-CoV2373, and leveled off after dose four. Unsolicited AEs were reported in 9% of participants after dose 4 (none severe or serious). Neutralization antibody titers increased following booster doses. Antigenic cartography demonstrated reductions in antigenic distance between ancestral and variant SARS-CoV-2 strains with increased number of NVX-CoV2373 doses.Conclusions A fourth dose of NVX-CoV2373 enhanced immunogenicity without increasing reactogenicity. Antigenic cartography demonstrated a more universal-like response against SARS-CoV-2 variants after a fourth dose of NVX-CoV2373, indicating that updates to the vaccine composition may not be warranted.Trial registration number NCT04368988Competing Interest StatementAll authors are contract or full-time employees of Novavax and as such receive a salary for their work.Clinical TrialNCT04368988Funding StatementThis study was funded by Novavax, Inc. and initially by the Coalition for Epidemic Preparedness Innovations (CEPI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the Alfred Hospital Ethics Committee (Melbourne, Victoria, Australia) and Advarra Central Institutional Review Board (Colombia, Maryland, USA). Safety oversight for the study was provided by an independent Safety Monitoring Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe trial protocol was a part of the peer-review process and will be included with the published manuscript; more information is available at https://clinicaltrials.gov/ct2/show/NCT04368988.